Immuneering (NASDAQ:IMRX) Given “Buy” Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $13.00 price objective on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of Immuneering in a research report on Thursday, April 10th.

Immuneering Stock Down 3.6 %

Shares of IMRX stock opened at $1.21 on Tuesday. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $3.83. The firm’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.80. The stock has a market cap of $43.36 million, a price-to-earnings ratio of -0.61 and a beta of -0.22.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). On average, equities analysts forecast that Immuneering will post -1.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. purchased a new stake in Immuneering during the 4th quarter worth approximately $390,000. First Manhattan CO. LLC. bought a new stake in shares of Immuneering in the fourth quarter worth $71,000. Bridgeway Capital Management LLC increased its stake in shares of Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after buying an additional 22,400 shares during the last quarter. Marshall Wace LLP acquired a new stake in Immuneering in the fourth quarter valued at $47,000. Finally, XTX Topco Ltd grew its holdings in Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after acquiring an additional 20,871 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.